Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Apr 14, 2023 4:40pm

134 Views

Post# 35396027

Recent News

AGN.c AGNPF continues to be a leader in stroke treatment space (market est. to reach value of $15B by 2027) as they completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for stroke and have been approved to move forward.

With this approval they continue to be on the cutting edge of both DMT applications and stroke research. Findings from the study have the potential to be groundbreaking.

More on the clinical study discussed in this recent interview with the CEO.

https://www.youtube.com/watch?v=2XM7SC5iQaI

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario